BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J 2008;8:85-9. [DOI: 10.1038/sj.tpj.6500457] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Smith TR. Chapter 29: Pharmacogenomics in Ethical and Social Contexts. Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process, 2nd Edition 2022. [DOI: 10.21019/9781582123844.ch29] [Reference Citation Analysis]
2 Haga SB. Revisiting Secondary Information Related to Pharmacogenetic Testing. Front Genet 2021;12:741395. [PMID: 34659361 DOI: 10.3389/fgene.2021.741395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu JC, Gorbovskaya I, Bousman C, Brown LC, Müller DJ. Opportunities and challenges of implementation models of pharmacogenomics in clinical practice. Personalized Psychiatry 2020. [DOI: 10.1016/b978-0-12-813176-3.00037-7] [Reference Citation Analysis]
4 Smith TR. Chapter 28: Pharmacogenomics in Ethical and Social Contexts. Pharmacogenomics: Foundations, Competencies, and the Pharmacists’ Patient Care Process 2020. [DOI: 10.21019/9781582123127.ch28] [Reference Citation Analysis]
5 Chambliss AB, Marzinke MA. Clinical Pharmacogenetics for Precision Medicine: Successes and Setbacks. J Appl Lab Med 2018;3:474-86. [PMID: 33636912 DOI: 10.1373/jalm.2017.023127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Zierhut HA, Campbell CA, Mitchell AG, Lemke AA, Mills R, Bishop JR. Collaborative Counseling Considerations for Pharmacogenomic Tests. Pharmacotherapy 2017;37:990-9. [DOI: 10.1002/phar.1980] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
7 Christensen KD, Roberts JS, Whitehouse PJ, Royal CD, Obisesan TO, Cupples LA, Vernarelli JA, Bhatt DL, Linnenbringer E, Butson MB, Fasaye GA, Uhlmann WR, Hiraki S, Wang N, Cook-Deegan R, Green RC; REVEAL Study Group*. Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 2016;164:155-63. [PMID: 26810768 DOI: 10.7326/M15-0187] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
8 Sing CW, Cheung CL, Wong IC. Pharmacogenomics--how close/far are we to practising individualized medicine for children? Br J Clin Pharmacol 2015;79:419-28. [PMID: 25855823 DOI: 10.1111/bcp.12338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
9 Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics 2014;15:1771-90. [PMID: 25493570 DOI: 10.2217/pgs.14.117] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
10 Haga SB, Moaddeb J. Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenet Genomics 2014;24:139-45. [PMID: 24384556 DOI: 10.1097/FPC.0000000000000028] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
11 Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol 2015;111:9-17. [PMID: 24992205 DOI: 10.1002/jso.23712] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
12 Sturm AC, Sweet K, Manickam K. Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional. Pharmacogenomics 2013;14:703-6. [PMID: 23651015 DOI: 10.2217/pgs.13.46] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Kocarnik JM, Fullerton SM. Returning pleiotropic results from genetic testing to patients and research participants. JAMA 2014;311:795-6. [PMID: 24481117 DOI: 10.1001/jama.2014.369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
14 Mills R, Haga SB. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics 2013;14:957-68. [PMID: 23746189 DOI: 10.2217/pgs.13.76] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
15 Mills R, Voora D, Peyser B, Haga SB. Delivering pharmacogenetic testing in a primary care setting. Pharmgenomics Pers Med 2013;6:105-12. [PMID: 24101877 DOI: 10.2147/PGPM.S50598] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
16 Brandt DS, Shinkunas L, Hillis SL, Daack-Hirsch SE, Driessnack M, Downing NR, Liu MF, Shah LL, Williams JK, Simon CM. A closer look at the recommended criteria for disclosing genetic results: perspectives of medical genetic specialists, genomic researchers, and institutional review board chairs. J Genet Couns 2013;22:544-53. [PMID: 23547023 DOI: 10.1007/s10897-013-9583-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
17 Westbrook MJ, Wright MF, Van Driest SL, McGregor TL, Denny JC, Zuvich RL, Clayton EW, Brothers KB. Mapping the incidentalome: estimating incidental findings generated through clinical pharmacogenomics testing. Genet Med 2013;15:325-31. [PMID: 23196672 DOI: 10.1038/gim.2012.147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
18 Downing NR, Williams JK, Daack-Hirsch S, Driessnack M, Simon CM. Genetics specialists' perspectives on disclosure of genomic incidental findings in the clinical setting. Patient Educ Couns 2013;90:133-8. [PMID: 23068909 DOI: 10.1016/j.pec.2012.09.010] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
19 Haga SB, O'Daniel JM, Tindall GM, Mills R, Lipkus IM, Agans R. Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing. Clin Genet 2012;82:115-20. [PMID: 22283474 DOI: 10.1111/j.1399-0004.2012.01848.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
20 Soo-jin Lee S. Ethical Considerations for Pharmacogenomics: Privacy and Confidentiality. Principles of Pharmacogenetics and Pharmacogenomics 2012. [DOI: 10.1017/cbo9781139051194.009] [Reference Citation Analysis]
21 Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. Genet Med 2011;13:723-8. [PMID: 21633294 DOI: 10.1097/GIM.0b013e31821afcc0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
22 Haga SB, Tindall G, O'Daniel JM. Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers 2012;16:193-7. [PMID: 22047505 DOI: 10.1089/gtmb.2011.0118] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
23 Haga SB, Tindall G, O'Daniel JM. Professional perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers 2012;16:21-4. [PMID: 21770772 DOI: 10.1089/gtmb.2011.0045] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
24 Howard HC, Joly Y, Avard D, Laplante N, Phillips M, Tardif JC. Informed consent in the context of pharmacogenomic research: ethical considerations. Pharmacogenomics J 2011;11:155-61. [PMID: 21445091 DOI: 10.1038/tpj.2011.11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
25 Laberge AM, Burke W. Clinical and public health implications of emerging genetic technologies. Semin Nephrol 2010;30:185-94. [PMID: 20347647 DOI: 10.1016/j.semnephrol.2010.01.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making 2010;30:328-40. [PMID: 20086232 DOI: 10.1177/0272989X09347014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
27 Veenstra DL, Garrison LP, Ramsey SD. Economic Issues and Genomic Medicine. Essentials of Genomic and Personalized Medicine 2010. [DOI: 10.1016/b978-0-12-374934-5.00020-9] [Reference Citation Analysis]
28 Avard D, Silverstein T, Sillon G, Joly Y. Researchers' perceptions of the ethical implications of pharmacogenomics research with children. Public Health Genomics 2009;12:191-201. [PMID: 19204423 DOI: 10.1159/000189633] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
29 Ries NM, Castle D. Nutrigenomics and ethics interface: direct-to-consumer services and commercial aspects. OMICS 2008;12:245-50. [PMID: 19040371 DOI: 10.1089/omi.2008.0049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
30 Haga SB, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet Med 2008;10:391-5. [PMID: 18496219 DOI: 10.1097/GIM.0b013e31817701d4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 49] [Article Influence: 2.7] [Reference Citation Analysis]